Magnesium Supplementation and Colonoscopy
Introduction to Magnesium and Colonoscopy Safety
- The American Gastroenterological Association recommends that patients discontinue magnesium-based supplements before colonoscopy, particularly if they have chronic kidney disease, renal impairment, congestive heart failure, or are elderly 1, 2
Key Safety Concerns
- Magnesium-based preparations should be avoided in patients with chronic kidney disease (creatinine clearance <60 mL/min/1.73 m²) due to the risk of hypermagnesemia and potential cardiac complications 1
- Patients with renal insufficiency (creatinine clearance <60 mL/min) should avoid magnesium supplementation due to the risk of life-threatening hypermagnesemia 1, 2
- Congestive heart failure patients (NYHA class III/IV or ejection fraction <50%) should avoid magnesium supplementation 1, 2
- Elderly patients ≥65 years should discontinue magnesium supplements due to increased risk of hyponatremia (absolute risk increase 0.05%, relative risk 2.4 for hospitalization) 2, 3
- Patients with pre-existing electrolyte disturbances should avoid magnesium supplementation 1
- Patients taking ACE inhibitors, NSAIDs, or diuretics should avoid magnesium supplementation due to increased hypermagnesemia risk 1
Clinical Rationale and Decision Algorithm
- The concern is not about therapeutic magnesium supplementation interfering with bowel preparation quality, but rather the additive effect of magnesium supplements combined with magnesium-containing bowel preparations (such as sodium picosulfate + magnesium citrate or magnesium citrate-based regimens) 2
- For patients currently taking magnesium supplements, assess renal function and discontinue magnesium supplements at least 48-72 hours before colonoscopy if creatinine clearance <60 mL/min 1, 2
- Evaluate cardiac status and discontinue magnesium supplements if patient has CHF or significant cardiac disease, and consider alternative bowel preparation without magnesium 1, 2
- Consider age and discontinue magnesium supplements in patients ≥65 years, and monitor for hyponatremia risk 2, 3